Edwards Lifesciences Corp.  (EW) Trade Now »     Rate EW  -  Discuss EW  -  Add to Watch List        

Filed under: Earnings reports, Baxter Intl (BAX), Technical Analysis, Stocks to Buy

Edwards Lifesciences Corporation (NYSE: EW) provides products and technologies designed to treat cardiovascular diseases. Offerings include tissue heart valves, valve repair products, heart monitoring equipment, central venous access devices and cardiac surgery system products. The company sells its goods through a direct sales force and independent distributors worldwide. Formerly part of Baxter International (NYSE: BAX), the firm was a year 2000 spin-off.

Edwards surprised the Street late last month, when it

Edwards LifeSciences (EW) is an interesting small/mid cap play in this market. First off, the company provides products and technologies designed to treat cardiovascular diseases. It focuses primarily on heart valve disease, peripheral vascular disease, and critical care technologies.

On April 22, the company raised its full-year sales and earnings guidance, citing strength in each of its product lines and reaping benefits from a weak dollar. The company expects profit between $2.45 and $2.53, a 13 cents-per-share increase in the range. Sales are expected to range from $1.21 bil